119
Views
6
CrossRef citations to date
0
Altmetric
IMAGING, DIAGNOSIS, PROGNOSIS

Distinguishing Non-Small Cell Lung Adenocarcinoma Patients from Squamous Cell Carcinoma Patients and Control Individuals Using Serum Profiling

, , , , , & show all
Pages 180-188 | Published online: 02 Feb 2012

REFERENCES

  • American Cancer Society. Cancer Facts & Figures. Atlanta, GA: American Cancer Society, 2010. http://www.cancer.org/docroot/ STT/content/STT_1x_Cancer_Facts__Figures_2010.asp?from=fast
  • Greenberg AK, Lee MS. Biomarkers for lung cancer: clinical uses. Curr Opin Pulmon Med 2007;13:249–255.
  • Cooper WA, O'Toole SO, Boyer M, Horvath L, Mahar A. What's new in non-small cell lung cancer for pathologists: the importance of accurate subtyping, EGFR mutations and ALK rearrangements. Pathology 2011;43:103–115.
  • Paech DC, Weston AR, Pavlakis N, Gill A, Rajan N, Barraclough H, Fitzgerald B, Van Kooten M. A systematic review of the interobserver variability for histology in the differentiation between squamous and nonsquamous non-small cell lung cancer. J Thorac Oncol 2011;6:55–63.
  • Ou SH, Zell JA. Carcinoma NOS is a common histologic diagnosis and is increasing in proportion among non-small cell lung cancer histologies. J Thorac Oncol 2009;4:1202–1211.
  • Terry J, Leung S, Laskin J, Leslie KO, Gown AM, Ionescu DN. Optimal immunohistochemical markers for distinguishing lung adenocarcinomas from squamous cell carcinomas in small tumor samples. Am J Surg Pathol 2010;34:1805–1811.
  • Richter R, Schuz-Knappe P, Schrader M, Ständker L, Jürgens M, Tammen H, Forssmann WG. Composition of the peptide fraction in human blood plasma: database of circulating human peptides. J Chromatog B Biomed Sci Appl 1999;726:25–35.
  • Chambers G, Lawrie L, Cash P, Murray GI. Proteomics: a new approach to the study of disease. J Pathol 2000;192:280–288.
  • Verma M, Wright GL Jr, Hanash SM, Gopal-Srivastava R, Srivastava S. Proteomic approaches within the NCI early detection research network for the discovery and identification of cancer biomarkers. Annal NY Acad Sci 2001;945:103–115.
  • Hanas JS, Hocker JR, Cheung JY, Larabee JL, Lerner MR, Lightfoot SA, Morgan DL, Denson KD, Prejeant KC, Gusev Y, Smith BJ, Hanas RJ, Postier RG, Brackett DJ. Biomarker identification in human pancreatic cancer sera. Pancreas 2008;36:61–69.
  • Semmes OJ, Feng Z, Adam BL, Banez LL, Bigbee WL, Campos D, Cazares LH, Chan DW, Grizzle WE, Izbicka E, Kagan J, Malik G, McLerran D, Moul JW, Partin A, Prasanna P, Rosenzweig J, Sokoll LJ, Srivastava S, Srivastava S, Thompson I, Welsh MJ, White N, Winget M, Yasui Y, Zhang Z, Zhu L. Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. Clin Chem 2005;51:102–112.
  • Hortin GL. Can mass spectrometric protein profiling meet desired standards of clinical laboratory practice? Clin Chem 2005;51: 3–5.
  • West-Nørager M, Bro R, Marini F, Høgdall EV, Høgdall CK, Nedergaard L, Heegaard NH. Feasibility of serodiagnosis of ovarian cancer by mass spectrometry. Anal Chem 2009;81:1907–1913.
  • Villanueva J, Shaffer DR, Philip J, Chaparro CA, Erdjument-Bromage H, Olshen AB, Fleisher M, Lilja H, Brogi E, Boyd J, Sanchez-Carbayo M, Holland EC, Cordon-Cardo C, Scher HI, Tempst P. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest 2006;116:271–284.
  • Sorace JM, Zhan M. A data review and re-assessment of ovarian cancer serum proteomic profiling. BMC Bioinform 2003;4:24.
  • Hocker JR, Lerner MR, Mitchell SL, Lightfoot SA, Lander TJ, Quillet AA, Hanas RJ, Peyton MD, Postier RG, Brackett DJ, Hanas JS. Distinguishing early clinical stages of pancreatic cancer using serum profiling. Cancer Invest 2011;29:173–179.
  • Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 2002;48:1296–1304.
  • Yang SY, Xiao XY, Zhang WG, Zhang LJ, Zhang W, Zhou B, Chen G, He DC. Application of serum SELDI proteomic patterns in diagnosis of lung cancer. BMC Cancer 2005;5(83):1–7.
  • Hocker JR, Peyton MD, Lerner MR, Mitchell SL, Lightfoot SA, Lander TJ, Bates-Albers LM, Vu NT, Hanas RJ, Kupiec TC, Brackett DJ, Hanas JS. Serum discrimination of early-stage lung cancer patients using electrospray-ionization mass spectrometry. Lung Cancer 2011;74:206–211.
  • Sobin LH, Wittekind C. International Union Against Cancer; TNM: Classification of Malignant Tumors, 6th edition. New York, NY: Wiley-Liss, 2002
  • Guan W, Zhou M, Hampton CY, Benigno BB, Walker LD, Gray A, McDonald JF, Fernández FM. Ovarian cancer detection from metabolomic liquid chromatography/mass spectrometry data by support vector machines. BMC Bioinform 2009;10:259–274.
  • Ransohoff DF. Rules of evidence for cancer molecular-marker discovery and validation. Nat Rev Cancer 2004;4:309–314.
  • Altman DG, Bland M. Statistics notes: diagnostic tests 2: predictive values. BMJ 1994;309:102.
  • Altman DG, Bland M. Statistics notes: diagnostic tests 1: sensitivity and specificity. BMJ 1994;308:1552.
  • National Committee for Clinical Laboratory Standards. User Evaluation of Precision Performance of Clinical Chemistry Devices. NCCLS Tentative Guideline EP5-T. Wayne, PA: NCCLS, 2004.
  • Postier RG, Lerner MR, Lightfoot SA, Vannarath R, Lane MM, Hanas JS, Brackett DJ. DNA ploidy and Markovian analysis of neoplastic progression in experimental pancreatic cancer. J Histochem Cytochem 2003;51:303–309.
  • Jordana KW, Adkinsa CB, Sud L, Halpernb EF, Marka EJ, Christianic, DC, Chenga LL. Comparison of squamous cell carcinoma and adenocarcinoma of the lung by metabolomic analysis of tissue—serum pairs. Lung Cancer 2010;68:44–50.
  • Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF 3rd, Gaudreault J, Damico LA, Holmgren E, Kabbinavar F. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 2004;22:2184–2191.
  • Del Vescovo V, Cantaloni C, Cucino A, Girlando S, Silvestri M, Bragantini E, Fasanella S, Cuorvo LV, Palma PD, Rossi G, Papotti M, Pelosi G, Graziano P, Cavazza A, Denti MA, Barbareschi M. MiR-205 expression levels in nonsmall cell lung cancer do not always distinguish adenocarcinomas from squamous cell carcinomas. Am Surg Pathol 2011;35:268–275.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.